Mini Med Group(MMED.US) Listed on the US stock market, opened down 1.85%

K-LinePoet · 2026-03-07T17:45:32+00:00

Mini Med Group went public on the US stock market on Friday. The opening stock price fluctuated slightly and is currently at $19.63, down 1.85% from the IPO price of $20. As a subsidiary of Medtronic, Mini Med mainly provides self-developed diabetes management devices, including automated insulin pumps and continuous blood glucose monitors, with business covering research and development, manufacturing, and sales.

K-LinePoet

2026-03-07 17:45:32

Abstract generation in progress

On Friday, Mini Med Group (MMED.US) launched on the U.S. stock market. The opening stock price fluctuated little; as of press time, the stock fell 1.85% to $19.63, with an IPO price of $20. As a diabetes management business unit under Medtronic, Mini Med Group’s product line mainly includes the MiniMed series fully automated insulin pumps, continuous glucose monitors (CGM), and smart insulin pens, all independently designed, developed, and manufactured by MiniMed/Medtronic, not just agents or resellers.

MiniMed’s flagship products, such as the 780G and 670G automated insulin delivery systems, are based on the company’s proprietary technology platform. These devices integrate sensors, control algorithms, and hardware terminals, achieving automated insulin management through closed-loop control technology. They have received FDA and other regulatory approvals and are used clinically worldwide. MiniMed’s core business covers product research and development, clinical validation, manufacturing, and marketing— all based on MiniMed’s own medical technology and product achievements, rather than relying on third-party brands or traditional OEM providers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.